Janis Taube, MD, MSc - Refining Best Practices in Cancer Immunotherapy Biomarker Testing and Pathologic Response Assessment

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/FTC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the cancer immunotherapy arsenal and its impact on patient care continues to expand, it’s more important than ever to refine testing for predictive biomarkers to guide patient selection and clinical decisions about treatment. Assessments of PD-L1 expression and MSI/MMR or TMB status have a role in some tumor types and treatment settings, but a number of challenges related to testing and interpretation of results remain, and better predictive tools are needed. There is also an increasing need for new ways to measure response to immunotherapies as they transition to early-stage, curative-intent settings in different solid tumors. Pathologic response assessment has emerged as a promising approach for evaluating the impact of neoadjuvant immunotherapy in lung, breast, and other cancers. However, limited guidance has been available on how to define and measure pathologic response, and report and apply assessment results. In this educational activity, experts provide up-to-date instruction and practical guidance on how to improve predictive immunotherapy biomarker testing and establish best practices for pathologic response assessment after neoadjuvant immunotherapy based on the evolving evidence, new guidelines, and illustrative case scenarios. Upon completion of this activity, participants should be better able to: Describe the recommendations and practical considerations for cancer immunotherapy biomarker testing and pathologic response assessment in different tumors and treatment settings; Perform appropriate immunotherapy biomarker testing and pathologic response assessment to cancer immunotherapies according to the latest evidence, requirements, and best practice recommendations across different tumors and treatment settings; and Implement effective strategies for multidisciplinary communication, collaboration, and coordination among pathologists, oncologists, pulmonologists, surgeons, and other care team professionals regarding selection and interpretation of immunotherapy biomarker tests and pathologic response assessment to guide clinical decision-making across different tumors and treatment settings